Merck (NYSE:MRK) announced Thursday that its bestselling therapy, Keytruda, as part of a combination regimen, reached the ...

As of March 31, 2025, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments, of $106.9 million. The Company believes that its current cash, cash ...